Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis

Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis

Abstract Background A number of studies have reported hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) after treatment with immune checkpoint inhibitor (ICI). This study aimed to summarize the incidence and survival outcome of HPD in NSCLC and identify the clinicopathological fea...

Full description

Bibliographic Details
Main Authors: Yan Chen, Junjie Hu, Fangfang Bu, Haiping Zhang, Ke Fei, Peng Zhang
Format: Article
Language:English
Published: BMC 2020-07-01
Series:BMC Cancer
Subjects:
Non-small cell lung cancer
Hyperprogressive disease
Immune checkpoint inhibitor
Immunotherapy
Meta-analysis
Online Access:http://link.springer.com/article/10.1186/s12885-020-07206-4

Internet

http://link.springer.com/article/10.1186/s12885-020-07206-4

Similar Items